Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Esophageal Squamous Cell Carcinoma 5Triple Negative Breast Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Small Cell Lung Carcinoma 1Salivary Gland Malignant Neoplasms 1Pathologic Complete Response 1Pancreatic cancer, adult 1Pancreatic Cancer Resectable 1Melanoma 1Mediastinal Neoplasms 1Locally Advanced Non-Small Cell Lung Cancer 1Gastric Adenocarcinoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Carcinoma 1Carcinoma 1Brain Neoplasms 1Anophthalmia with pulmonary hypoplasia 1Advanced Triple Negative Breast Cancer 1

Interventions

Cisplatin 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Carcinoma × 130-nm albumin-bound paclitaxel × Clear all
NCT07490002 2026-03-24

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

Changhai Hospital

Phase 2 Not yet recruiting
33 enrolled
Gastrointestinal

Esophageal Squamous Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡